ARS Pharmaceuticals Inc
NASDAQ:SPRY

Watchlist Manager
ARS Pharmaceuticals Inc Logo
ARS Pharmaceuticals Inc
NASDAQ:SPRY
Watchlist
Price: 17.28 USD 2.98% Market Closed
Market Cap: 1.7B USD

Intrinsic Value

The intrinsic value of one SPRY stock under the Base Case scenario is 17.56 USD. Compared to the current market price of 17.28 USD, ARS Pharmaceuticals Inc is Undervalued by 2%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

SPRY Intrinsic Value
17.56 USD
Undervaluation 2%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
ARS Pharmaceuticals Inc

Valuation History Unavailable

Historical valuation for SPRY cannot be conducted due to limitations such as insufficient data or other constraints.

Valuation In Progress...
Valuation In Progress...
0%
Compare SPRY to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about SPRY?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about ARS Pharmaceuticals Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
ARS Pharmaceuticals Inc

Current Assets 303.9m
Cash & Short-Term Investments 275.7m
Receivables 10.3m
Other Current Assets 17.9m
Non-Current Assets 23.5m
PP&E 1.1m
Intangibles 7.2m
Other Non-Current Assets 15.1m
Efficiency

Free Cash Flow Analysis
ARS Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
ARS Pharmaceuticals Inc

Revenue
97.1m USD
Cost of Revenue
-2.6m USD
Gross Profit
94.6m USD
Operating Expenses
-121.6m USD
Operating Income
-27.1m USD
Other Expenses
11.4m USD
Net Income
-15.7m USD
Fundamental Scores

SPRY Profitability Score
Profitability Due Diligence

ARS Pharmaceuticals Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
ROE is Increasing
ROIC is Increasing
33/100
Profitability
Score

ARS Pharmaceuticals Inc's profitability score is 33/100. The higher the profitability score, the more profitable the company is.

SPRY Solvency Score
Solvency Due Diligence

ARS Pharmaceuticals Inc's solvency score is 79/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Low D/E
Long-Term Solvency
79/100
Solvency
Score

ARS Pharmaceuticals Inc's solvency score is 79/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

SPRY Price Targets Summary
ARS Pharmaceuticals Inc

Wall Street analysts forecast SPRY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for SPRY is 32.23 USD with a low forecast of 26.26 USD and a high forecast of 42 USD.

Lowest
Price Target
26.26 USD
52% Upside
Average
Price Target
32.23 USD
87% Upside
Highest
Price Target
42 USD
143% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

ARS Pharmaceuticals Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for SPRY is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

SPRY Insider Trading
Buy and sell transactions by insiders

SPRY News

Other Videos
What is the Intrinsic Value of one SPRY stock?

The intrinsic value of one SPRY stock under the Base Case scenario is 17.56 USD.

Is SPRY stock undervalued or overvalued?

Compared to the current market price of 17.28 USD, ARS Pharmaceuticals Inc is Undervalued by 2%.

Back to Top